← Oncology Approval Tracker

FDA DECISION ·

Breyanzi

lisocabtagene maraleucel · Juno Therapeutics / Bristol Myers Squibb

FDA approvalNew or expanded indicationLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months of it, or refractory or relapsing after first line and ineligible for hematopoietic stem cell transplantation due to age or comorbidities.

LAMPGEN ANALYSIS

Why it matters

The action reaches early-relapsing disease and a separate group unable to proceed to transplant.

What research teams should watch

Record the relapse interval and the rationale for transplant ineligibility. Coordinate CAR T referral and collection.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

CAR T-cell studies in relapsed or refractory DLBCL

PRIMARY RECORDS

Sources